Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It is indicated for relief of menopausal vasomotor symptoms, treatment of hypoestrogenism, and prevention of osteoporosis in postmenopausal women, providing systemic estrogen levels via skin absorption.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across EU and global markets.

Lenzetto (estradiol) acts on the estrogen pathway to address several hormone‑related conditions.

Menopausal vasomotor symptoms: reduces hot flashes and night sweats. Hypoestrogenism: restores estrogen levels in women with deficient endogenous production. Postmenopausal osteoporosis prevention: helps maintain bone mineral density and reduce fracture risk. Urogenital atrophy: improves vaginal tissue health and reduces dryness.

Common Side Effects: - Skin irritation at the application site - Nausea - Headache - Breast tenderness - Mild abdominal cramps - Mood changes

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke - Hormone‑dependent cancer progression - Severe allergic reaction (anaphylaxis) - Hepatotoxicity

Before prescribing Lenzetto, consider the following precautions: - Assess cardiovascular risk: evaluate history of thromboembolic events before initiating therapy. - Screen for hormone‑sensitive malignancies: avoid in active breast or endometrial cancer. - Monitor liver function: adjust if hepatic impairment is present. - Consider bone health: use as part of osteoporosis management plan. - Avoid use during pregnancy: contraindicated in pregnant women. - Store at room temperature: keep patch in original packaging, protect from moisture and direct sunlight.

Lenzetto may interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Combined oral contraceptives containing estrogen: increase risk of thromboembolism. - Anticoagulants (warfarin, DOACs): may potentiate bleeding risk. - Selective estrogen receptor modulators (tamoxifen, raloxifene): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, erythromycin): may raise estradiol levels. - CYP3A4 inducers (rifampin, carbamazepine): may reduce estradiol exposure. - Thyroid hormone replacement: may require dose adjustment.